Physiologically-Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID-19 in Geriatrics.

ABSTRACT: Janus kinase (JAK) inhibitors baricitinib and tofacitinib are recommended by the US National Institutes of Health as immunomodulatory drugs for coronavirus disease 2019 (COVID-19) treatment. In addition, baricitinib has recently received Emergency Use Authorization from the US Food and Drug Administration, although the instruction provided dosing information only for adults. Geriatrics with organ dysfunction are one of the most vulnerable cohorts when combating the pandemic. The aim of the present work was to evaluate current dosing strategies of baricitinib and tofacitinib for potential COVID-19 treatment for White and Chinese geriatric patients with chronic renal impairment. An established physiologically-based pharmacokinetic (PBPK) modeling framework for age-dependent simulations was u

SUBMITTER: Wang Z 

PROVIDER: S-EPMC9087009 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature